Quick Answer
Processa Pharmaceuticals, Inc. reported Stockholders Equity of $5.58 million for the year ending 2025.
- Processa Pharmaceuticals, Inc. showed an increase of +228.8% in Stockholders Equity from 2024 to 2025.
- This data is from Processa Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2016: -$2.35 million | Q1 2017: -$2.44 million | Q2 2017: -$2.49 million | Q3 2017: -$35.1 thousand | Q1 2018: $7.28 million | Q2 2018: $11.31 million | Q3 2018: $10.51 million | Q1 2019: $9.12 million | Q2 2019: $8.50 million | Q3 2019: $8.67 million | Q1 2020: $7.23 million | Q2 2020: $6.59 million | Q3 2020: $5.53 million | Q1 2021: $31.34 million | Q2 2021: $29.24 million | Q3 2021: $27.21 million | Q1 2022: $23.24 million | Q2 2022: $20.08 million | Q3 2022: $17.24 million | Q1 2023: $10.14 million | Q2 2023: $9.16 million | Q3 2023: $7.17 million | Q1 2024: $8.88 million | Q2 2024: $6.02 million | Q3 2024: $3.72 million | Q1 2025: $3.53 million | Q2 2025: $6.11 million | Q3 2025: $5.83 million.
- Over the full 14 years of available data (2012 to 2025), Processa Pharmaceuticals, Inc.'s Stockholders Equity has grown by 117.7%.
- Historical annual values: Fiscal year 2025: $5.58 million | Fiscal year 2024: $1.70 million | Fiscal year 2023: $4.99 million | Fiscal year 2022: $7.47 million | Fiscal year 2021: $25.49 million | Fiscal year 2020: $22.94 million | Fiscal year 2019: $8.01 million | Fiscal year 2018: $9.70 million | Fiscal year 2017: $373.2 thousand | Fiscal year 2016: -$2.27 million | Fiscal year 2015: -$85.7 thousand | Fiscal year 2014: $1.21 million | Fiscal year 2013: $1.67 million | Fiscal year 2012: $2.56 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: